nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—IRAK1—rheumatoid arthritis	0.361	0.649	CbGaD
Afatinib—BLK—rheumatoid arthritis	0.195	0.351	CbGaD
Afatinib—ABCG2—Leflunomide—rheumatoid arthritis	0.0437	0.22	CbGbCtD
Afatinib—ERBB2—duct of salivary gland—rheumatoid arthritis	0.0293	0.644	CbGeAlD
Afatinib—ABCG2—Sulfasalazine—rheumatoid arthritis	0.027	0.136	CbGbCtD
Afatinib—ABCG2—Hydrocortisone—rheumatoid arthritis	0.0217	0.109	CbGbCtD
Afatinib—ABCG2—Cyclosporine—rheumatoid arthritis	0.0205	0.103	CbGbCtD
Afatinib—ABCG2—Dexamethasone—rheumatoid arthritis	0.0135	0.0679	CbGbCtD
Afatinib—ABCB1—Methylprednisolone—rheumatoid arthritis	0.0129	0.0648	CbGbCtD
Afatinib—ABCG2—Methotrexate—rheumatoid arthritis	0.0108	0.0546	CbGbCtD
Afatinib—ABCB1—Betamethasone—rheumatoid arthritis	0.00836	0.0421	CbGbCtD
Afatinib—ABCB1—Prednisolone—rheumatoid arthritis	0.00825	0.0416	CbGbCtD
Afatinib—ABCB1—Hydrocortisone—rheumatoid arthritis	0.00782	0.0394	CbGbCtD
Afatinib—ABCB1—Prednisone—rheumatoid arthritis	0.00779	0.0392	CbGbCtD
Afatinib—ABCB1—Cyclosporine—rheumatoid arthritis	0.00738	0.0372	CbGbCtD
Afatinib—ABCB1—Dexamethasone—rheumatoid arthritis	0.00486	0.0245	CbGbCtD
Afatinib—ABCB1—Methotrexate—rheumatoid arthritis	0.00391	0.0197	CbGbCtD
Afatinib—ERBB2—exocrine gland—rheumatoid arthritis	0.0026	0.0572	CbGeAlD
Afatinib—Gefitinib—IRAK1—rheumatoid arthritis	0.00165	0.493	CrCbGaD
Afatinib—ERBB2—saliva-secreting gland—rheumatoid arthritis	0.0013	0.0285	CbGeAlD
Afatinib—ERBB4—saliva-secreting gland—rheumatoid arthritis	0.0013	0.0285	CbGeAlD
Afatinib—BLK—lymphoid tissue—rheumatoid arthritis	0.00127	0.028	CbGeAlD
Afatinib—ERBB2—connective tissue—rheumatoid arthritis	0.00119	0.0262	CbGeAlD
Afatinib—Vandetanib—BLK—rheumatoid arthritis	0.000937	0.28	CrCbGaD
Afatinib—PHKG2—tendon—rheumatoid arthritis	0.000912	0.0201	CbGeAlD
Afatinib—ERBB2—lymphoid tissue—rheumatoid arthritis	0.000872	0.0192	CbGeAlD
Afatinib—ERBB2—digestive system—rheumatoid arthritis	0.000861	0.0189	CbGeAlD
Afatinib—DYRK1A—lymphoid tissue—rheumatoid arthritis	0.000839	0.0185	CbGeAlD
Afatinib—ERBB4—tendon—rheumatoid arthritis	0.00082	0.018	CbGeAlD
Afatinib—IRAK1—tendon—rheumatoid arthritis	0.000613	0.0135	CbGeAlD
Afatinib—ABL1—parotid gland—rheumatoid arthritis	0.000568	0.0125	CbGeAlD
Afatinib—ABL1—saliva-secreting gland—rheumatoid arthritis	0.000544	0.012	CbGeAlD
Afatinib—ABL1—connective tissue—rheumatoid arthritis	0.0005	0.011	CbGeAlD
Afatinib—Vandetanib—VEGFA—rheumatoid arthritis	0.000498	0.149	CrCbGaD
Afatinib—ABL1—lymphoid tissue—rheumatoid arthritis	0.000365	0.00804	CbGeAlD
Afatinib—ABL1—digestive system—rheumatoid arthritis	0.000361	0.00794	CbGeAlD
Afatinib—ABCG2—parotid gland—rheumatoid arthritis	0.000358	0.00788	CbGeAlD
Afatinib—ABL1—tendon—rheumatoid arthritis	0.000343	0.00755	CbGeAlD
Afatinib—ABCG2—saliva-secreting gland—rheumatoid arthritis	0.000343	0.00754	CbGeAlD
Afatinib—ERBB2—Exemestane—Methylprednisolone—rheumatoid arthritis	0.000259	0.102	CbGdCrCtD
Afatinib—ERBB2—Exemestane—Prednisone—rheumatoid arthritis	0.000236	0.093	CbGdCrCtD
Afatinib—ERBB2—Exemestane—Prednisolone—rheumatoid arthritis	0.00023	0.0908	CbGdCrCtD
Afatinib—Bladder pain—Methotrexate—rheumatoid arthritis	0.00016	0.00231	CcSEcCtD
Afatinib—Infestation—Hydrocortisone—rheumatoid arthritis	0.000159	0.0023	CcSEcCtD
Afatinib—Infestation NOS—Hydrocortisone—rheumatoid arthritis	0.000159	0.0023	CcSEcCtD
Afatinib—Urinary tract disorder—Cyclosporine—rheumatoid arthritis	0.000159	0.00229	CcSEcCtD
Afatinib—Conjunctivitis—Prednisolone—rheumatoid arthritis	0.000159	0.00229	CcSEcCtD
Afatinib—Cough—Leflunomide—rheumatoid arthritis	0.000158	0.00229	CcSEcCtD
Afatinib—Connective tissue disorder—Cyclosporine—rheumatoid arthritis	0.000158	0.00228	CcSEcCtD
Afatinib—Urethral disorder—Cyclosporine—rheumatoid arthritis	0.000158	0.00228	CcSEcCtD
Afatinib—Upper respiratory tract infection—Triamcinolone—rheumatoid arthritis	0.000156	0.00226	CcSEcCtD
Afatinib—Infection—Azathioprine—rheumatoid arthritis	0.000156	0.00225	CcSEcCtD
Afatinib—Sepsis—Methotrexate—rheumatoid arthritis	0.000154	0.00222	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—rheumatoid arthritis	0.000153	0.00222	CcSEcCtD
Afatinib—Skin disorder—Azathioprine—rheumatoid arthritis	0.000152	0.0022	CcSEcCtD
Afatinib—Infestation—Methylprednisolone—rheumatoid arthritis	0.00015	0.00216	CcSEcCtD
Afatinib—Infestation NOS—Methylprednisolone—rheumatoid arthritis	0.00015	0.00216	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Hydrocortisone—rheumatoid arthritis	0.000149	0.0588	CbGdCrCtD
Afatinib—Infection—Leflunomide—rheumatoid arthritis	0.000147	0.00212	CcSEcCtD
Afatinib—Conjunctivitis—Triamcinolone—rheumatoid arthritis	0.000146	0.0021	CcSEcCtD
Afatinib—Nervous system disorder—Leflunomide—rheumatoid arthritis	0.000145	0.0021	CcSEcCtD
Afatinib—Mediastinal disorder—Cyclosporine—rheumatoid arthritis	0.000145	0.00209	CcSEcCtD
Afatinib—Skin disorder—Leflunomide—rheumatoid arthritis	0.000144	0.00208	CcSEcCtD
Afatinib—Alopecia—Cyclosporine—rheumatoid arthritis	0.000142	0.00205	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Hydrocortisone—rheumatoid arthritis	0.000142	0.0559	CbGdCrCtD
Afatinib—Epistaxis—Triamcinolone—rheumatoid arthritis	0.000142	0.00204	CcSEcCtD
Afatinib—Dry skin—Prednisone—rheumatoid arthritis	0.000141	0.00204	CcSEcCtD
Afatinib—Mental disorder—Cyclosporine—rheumatoid arthritis	0.000141	0.00204	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Methylprednisolone—rheumatoid arthritis	0.000141	0.0555	CbGdCrCtD
Afatinib—Connective tissue disorder—Hydrocortisone—rheumatoid arthritis	0.000141	0.00203	CcSEcCtD
Afatinib—Malnutrition—Cyclosporine—rheumatoid arthritis	0.00014	0.00202	CcSEcCtD
Afatinib—Hypokalaemia—Prednisone—rheumatoid arthritis	0.00014	0.00202	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Betamethasone—rheumatoid arthritis	0.000139	0.0546	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Dexamethasone—rheumatoid arthritis	0.000139	0.0546	CbGdCrCtD
Afatinib—Weight decreased—Betamethasone—rheumatoid arthritis	0.000138	0.00199	CcSEcCtD
Afatinib—Weight decreased—Dexamethasone—rheumatoid arthritis	0.000138	0.00199	CcSEcCtD
Afatinib—Dysgeusia—Cyclosporine—rheumatoid arthritis	0.000137	0.00198	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Prednisone—rheumatoid arthritis	0.000136	0.00196	CcSEcCtD
Afatinib—Gastrointestinal disorder—Azathioprine—rheumatoid arthritis	0.000135	0.00196	CcSEcCtD
Afatinib—Muscle spasms—Cyclosporine—rheumatoid arthritis	0.000135	0.00194	CcSEcCtD
Afatinib—Insomnia—Leflunomide—rheumatoid arthritis	0.000134	0.00193	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Methylprednisolone—rheumatoid arthritis	0.000134	0.0527	CbGdCrCtD
Afatinib—Vandetanib—ALB—rheumatoid arthritis	0.000134	0.04	CrCbGaD
Afatinib—Eye disorder—Hydrocortisone—rheumatoid arthritis	0.000134	0.00193	CcSEcCtD
Afatinib—Conjunctivitis—Dexamethasone—rheumatoid arthritis	0.000132	0.00191	CcSEcCtD
Afatinib—Conjunctivitis—Betamethasone—rheumatoid arthritis	0.000132	0.00191	CcSEcCtD
Afatinib—Dyspnoea—Leflunomide—rheumatoid arthritis	0.000132	0.00191	CcSEcCtD
Afatinib—Connective tissue disorder—Methylprednisolone—rheumatoid arthritis	0.000132	0.00191	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Betamethasone—rheumatoid arthritis	0.000132	0.0519	CbGdCrCtD
Afatinib—ERBB2—Desoximetasone—Dexamethasone—rheumatoid arthritis	0.000132	0.0519	CbGdCrCtD
Afatinib—Dyspepsia—Leflunomide—rheumatoid arthritis	0.00013	0.00188	CcSEcCtD
Afatinib—Decreased appetite—Leflunomide—rheumatoid arthritis	0.000129	0.00186	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Triamcinolone—rheumatoid arthritis	0.000129	0.0507	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Prednisone—rheumatoid arthritis	0.000129	0.0507	CbGdCrCtD
Afatinib—Gastrointestinal disorder—Leflunomide—rheumatoid arthritis	0.000128	0.00185	CcSEcCtD
Afatinib—Fatigue—Leflunomide—rheumatoid arthritis	0.000128	0.00184	CcSEcCtD
Afatinib—Gefitinib—ALB—rheumatoid arthritis	0.000127	0.038	CrCbGaD
Afatinib—Constipation—Leflunomide—rheumatoid arthritis	0.000127	0.00183	CcSEcCtD
Afatinib—Eye disorder—Methylprednisolone—rheumatoid arthritis	0.000126	0.00181	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Prednisolone—rheumatoid arthritis	0.000126	0.0494	CbGdCrCtD
Afatinib—Mental disorder—Hydrocortisone—rheumatoid arthritis	0.000125	0.00181	CcSEcCtD
Afatinib—Malnutrition—Hydrocortisone—rheumatoid arthritis	0.000125	0.0018	CcSEcCtD
Afatinib—Body temperature increased—Azathioprine—rheumatoid arthritis	0.000124	0.00179	CcSEcCtD
Afatinib—Cough—Cyclosporine—rheumatoid arthritis	0.000122	0.00176	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Prednisone—rheumatoid arthritis	0.000122	0.0481	CbGdCrCtD
Afatinib—Mediastinal disorder—Methylprednisolone—rheumatoid arthritis	0.000121	0.00175	CcSEcCtD
Afatinib—Weight decreased—Prednisone—rheumatoid arthritis	0.00012	0.00174	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Prednisolone—rheumatoid arthritis	0.000119	0.047	CbGdCrCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—rheumatoid arthritis	0.000118	0.00171	CcSEcCtD
Afatinib—Mental disorder—Methylprednisolone—rheumatoid arthritis	0.000118	0.0017	CcSEcCtD
Afatinib—Body temperature increased—Leflunomide—rheumatoid arthritis	0.000117	0.00169	CcSEcCtD
Afatinib—Malnutrition—Methylprednisolone—rheumatoid arthritis	0.000117	0.00169	CcSEcCtD
Afatinib—Dysgeusia—Triamcinolone—rheumatoid arthritis	0.000115	0.00166	CcSEcCtD
Afatinib—Eye disorder—Dexamethasone—rheumatoid arthritis	0.000114	0.00165	CcSEcCtD
Afatinib—Eye disorder—Betamethasone—rheumatoid arthritis	0.000114	0.00165	CcSEcCtD
Afatinib—ABCB1—lymphoid tissue—rheumatoid arthritis	0.000114	0.0025	CbGeAlD
Afatinib—Infection—Cyclosporine—rheumatoid arthritis	0.000114	0.00164	CcSEcCtD
Afatinib—Back pain—Triamcinolone—rheumatoid arthritis	0.000113	0.00164	CcSEcCtD
Afatinib—ABCB1—digestive system—rheumatoid arthritis	0.000112	0.00247	CbGeAlD
Afatinib—Nervous system disorder—Cyclosporine—rheumatoid arthritis	0.000112	0.00162	CcSEcCtD
Afatinib—Skin disorder—Cyclosporine—rheumatoid arthritis	0.000111	0.0016	CcSEcCtD
Afatinib—Alopecia—Dexamethasone—rheumatoid arthritis	0.000108	0.00156	CcSEcCtD
Afatinib—Alopecia—Betamethasone—rheumatoid arthritis	0.000108	0.00156	CcSEcCtD
Afatinib—Diarrhoea—Azathioprine—rheumatoid arthritis	0.000107	0.00155	CcSEcCtD
Afatinib—Asthenia—Leflunomide—rheumatoid arthritis	0.000106	0.00153	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—rheumatoid arthritis	0.000105	0.00152	CcSEcCtD
Afatinib—Pruritus—Leflunomide—rheumatoid arthritis	0.000105	0.00151	CcSEcCtD
Afatinib—Connective tissue disorder—Prednisone—rheumatoid arthritis	0.000105	0.00151	CcSEcCtD
Afatinib—Dizziness—Azathioprine—rheumatoid arthritis	0.000104	0.0015	CcSEcCtD
Afatinib—Insomnia—Cyclosporine—rheumatoid arthritis	0.000103	0.00149	CcSEcCtD
Afatinib—Upper respiratory tract infection—Methotrexate—rheumatoid arthritis	0.000103	0.00149	CcSEcCtD
Afatinib—Cough—Triamcinolone—rheumatoid arthritis	0.000102	0.00148	CcSEcCtD
Afatinib—Dyspnoea—Cyclosporine—rheumatoid arthritis	0.000102	0.00147	CcSEcCtD
Afatinib—Diarrhoea—Leflunomide—rheumatoid arthritis	0.000101	0.00146	CcSEcCtD
Afatinib—Infection—Hydrocortisone—rheumatoid arthritis	0.000101	0.00146	CcSEcCtD
Afatinib—Dyspepsia—Cyclosporine—rheumatoid arthritis	0.000101	0.00145	CcSEcCtD
Afatinib—Vomiting—Azathioprine—rheumatoid arthritis	9.98e-05	0.00144	CcSEcCtD
Afatinib—Nervous system disorder—Hydrocortisone—rheumatoid arthritis	9.97e-05	0.00144	CcSEcCtD
Afatinib—Pneumonia—Methotrexate—rheumatoid arthritis	9.97e-05	0.00144	CcSEcCtD
Afatinib—Eye disorder—Prednisone—rheumatoid arthritis	9.95e-05	0.00144	CcSEcCtD
Afatinib—Decreased appetite—Cyclosporine—rheumatoid arthritis	9.94e-05	0.00143	CcSEcCtD
Afatinib—Infestation NOS—Methotrexate—rheumatoid arthritis	9.91e-05	0.00143	CcSEcCtD
Afatinib—Infestation—Methotrexate—rheumatoid arthritis	9.91e-05	0.00143	CcSEcCtD
Afatinib—Rash—Azathioprine—rheumatoid arthritis	9.89e-05	0.00143	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—rheumatoid arthritis	9.89e-05	0.00143	CcSEcCtD
Afatinib—Dermatitis—Azathioprine—rheumatoid arthritis	9.88e-05	0.00143	CcSEcCtD
Afatinib—Gastrointestinal disorder—Cyclosporine—rheumatoid arthritis	9.87e-05	0.00142	CcSEcCtD
Afatinib—Skin disorder—Hydrocortisone—rheumatoid arthritis	9.87e-05	0.00142	CcSEcCtD
Afatinib—Fatigue—Cyclosporine—rheumatoid arthritis	9.86e-05	0.00142	CcSEcCtD
Afatinib—Headache—Azathioprine—rheumatoid arthritis	9.83e-05	0.00142	CcSEcCtD
Afatinib—Dizziness—Leflunomide—rheumatoid arthritis	9.8e-05	0.00141	CcSEcCtD
Afatinib—Constipation—Cyclosporine—rheumatoid arthritis	9.78e-05	0.00141	CcSEcCtD
Afatinib—Renal failure—Methotrexate—rheumatoid arthritis	9.74e-05	0.00141	CcSEcCtD
Afatinib—Stomatitis—Methotrexate—rheumatoid arthritis	9.66e-05	0.00139	CcSEcCtD
Afatinib—Conjunctivitis—Methotrexate—rheumatoid arthritis	9.63e-05	0.00139	CcSEcCtD
Afatinib—Infection—Triamcinolone—rheumatoid arthritis	9.51e-05	0.00137	CcSEcCtD
Afatinib—Infection—Methylprednisolone—rheumatoid arthritis	9.48e-05	0.00137	CcSEcCtD
Afatinib—Vomiting—Leflunomide—rheumatoid arthritis	9.42e-05	0.00136	CcSEcCtD
Afatinib—Insomnia—Prednisolone—rheumatoid arthritis	9.41e-05	0.00136	CcSEcCtD
Afatinib—Alopecia—Prednisone—rheumatoid arthritis	9.4e-05	0.00136	CcSEcCtD
Afatinib—Hepatobiliary disease—Methotrexate—rheumatoid arthritis	9.37e-05	0.00135	CcSEcCtD
Afatinib—Nervous system disorder—Methylprednisolone—rheumatoid arthritis	9.36e-05	0.00135	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—rheumatoid arthritis	9.35e-05	0.00135	CcSEcCtD
Afatinib—Rash—Leflunomide—rheumatoid arthritis	9.34e-05	0.00135	CcSEcCtD
Afatinib—Dermatitis—Leflunomide—rheumatoid arthritis	9.33e-05	0.00135	CcSEcCtD
Afatinib—Mental disorder—Prednisone—rheumatoid arthritis	9.32e-05	0.00135	CcSEcCtD
Afatinib—Nausea—Azathioprine—rheumatoid arthritis	9.32e-05	0.00135	CcSEcCtD
Afatinib—Headache—Leflunomide—rheumatoid arthritis	9.28e-05	0.00134	CcSEcCtD
Afatinib—Skin disorder—Methylprednisolone—rheumatoid arthritis	9.27e-05	0.00134	CcSEcCtD
Afatinib—Malnutrition—Prednisone—rheumatoid arthritis	9.26e-05	0.00134	CcSEcCtD
Afatinib—Insomnia—Hydrocortisone—rheumatoid arthritis	9.19e-05	0.00133	CcSEcCtD
Afatinib—Body temperature increased—Cyclosporine—rheumatoid arthritis	9.04e-05	0.0013	CcSEcCtD
Afatinib—Dyspepsia—Hydrocortisone—rheumatoid arthritis	8.95e-05	0.00129	CcSEcCtD
Afatinib—Decreased appetite—Hydrocortisone—rheumatoid arthritis	8.83e-05	0.00128	CcSEcCtD
Afatinib—Nausea—Leflunomide—rheumatoid arthritis	8.8e-05	0.00127	CcSEcCtD
Afatinib—Urinary tract disorder—Methotrexate—rheumatoid arthritis	8.78e-05	0.00127	CcSEcCtD
Afatinib—Gastrointestinal disorder—Hydrocortisone—rheumatoid arthritis	8.77e-05	0.00127	CcSEcCtD
Afatinib—Fatigue—Hydrocortisone—rheumatoid arthritis	8.76e-05	0.00126	CcSEcCtD
Afatinib—Urethral disorder—Methotrexate—rheumatoid arthritis	8.72e-05	0.00126	CcSEcCtD
Afatinib—Insomnia—Triamcinolone—rheumatoid arthritis	8.65e-05	0.00125	CcSEcCtD
Afatinib—Insomnia—Methylprednisolone—rheumatoid arthritis	8.64e-05	0.00125	CcSEcCtD
Afatinib—Infection—Betamethasone—rheumatoid arthritis	8.63e-05	0.00125	CcSEcCtD
Afatinib—Infection—Dexamethasone—rheumatoid arthritis	8.63e-05	0.00125	CcSEcCtD
Afatinib—Dyspnoea—Triamcinolone—rheumatoid arthritis	8.53e-05	0.00123	CcSEcCtD
Afatinib—Nervous system disorder—Betamethasone—rheumatoid arthritis	8.51e-05	0.00123	CcSEcCtD
Afatinib—Nervous system disorder—Dexamethasone—rheumatoid arthritis	8.51e-05	0.00123	CcSEcCtD
Afatinib—Dyspepsia—Triamcinolone—rheumatoid arthritis	8.42e-05	0.00122	CcSEcCtD
Afatinib—Dyspepsia—Methylprednisolone—rheumatoid arthritis	8.4e-05	0.00121	CcSEcCtD
Afatinib—Eye disorder—Methotrexate—rheumatoid arthritis	8.31e-05	0.0012	CcSEcCtD
Afatinib—ERBB2—Levonorgestrel—Hydrocortisone—rheumatoid arthritis	8.29e-05	0.0327	CbGdCrCtD
Afatinib—Fatigue—Triamcinolone—rheumatoid arthritis	8.25e-05	0.00119	CcSEcCtD
Afatinib—Fatigue—Methylprednisolone—rheumatoid arthritis	8.23e-05	0.00119	CcSEcCtD
Afatinib—Asthenia—Cyclosporine—rheumatoid arthritis	8.2e-05	0.00118	CcSEcCtD
Afatinib—Pruritus—Cyclosporine—rheumatoid arthritis	8.09e-05	0.00117	CcSEcCtD
Afatinib—Body temperature increased—Hydrocortisone—rheumatoid arthritis	8.03e-05	0.00116	CcSEcCtD
Afatinib—Mediastinal disorder—Methotrexate—rheumatoid arthritis	8.02e-05	0.00116	CcSEcCtD
Afatinib—Alopecia—Methotrexate—rheumatoid arthritis	7.86e-05	0.00113	CcSEcCtD
Afatinib—Insomnia—Dexamethasone—rheumatoid arthritis	7.85e-05	0.00113	CcSEcCtD
Afatinib—Insomnia—Betamethasone—rheumatoid arthritis	7.85e-05	0.00113	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—rheumatoid arthritis	7.83e-05	0.00113	CcSEcCtD
Afatinib—Diarrhoea—Cyclosporine—rheumatoid arthritis	7.82e-05	0.00113	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—rheumatoid arthritis	7.79e-05	0.00112	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—rheumatoid arthritis	7.74e-05	0.00112	CcSEcCtD
Afatinib—Dyspepsia—Dexamethasone—rheumatoid arthritis	7.64e-05	0.0011	CcSEcCtD
Afatinib—Dyspepsia—Betamethasone—rheumatoid arthritis	7.64e-05	0.0011	CcSEcCtD
Afatinib—Dysgeusia—Methotrexate—rheumatoid arthritis	7.58e-05	0.00109	CcSEcCtD
Afatinib—Body temperature increased—Triamcinolone—rheumatoid arthritis	7.56e-05	0.00109	CcSEcCtD
Afatinib—Dizziness—Cyclosporine—rheumatoid arthritis	7.56e-05	0.00109	CcSEcCtD
Afatinib—Decreased appetite—Betamethasone—rheumatoid arthritis	7.55e-05	0.00109	CcSEcCtD
Afatinib—Decreased appetite—Dexamethasone—rheumatoid arthritis	7.55e-05	0.00109	CcSEcCtD
Afatinib—Infection—Prednisone—rheumatoid arthritis	7.51e-05	0.00108	CcSEcCtD
Afatinib—Gastrointestinal disorder—Betamethasone—rheumatoid arthritis	7.5e-05	0.00108	CcSEcCtD
Afatinib—Gastrointestinal disorder—Dexamethasone—rheumatoid arthritis	7.5e-05	0.00108	CcSEcCtD
Afatinib—Back pain—Methotrexate—rheumatoid arthritis	7.49e-05	0.00108	CcSEcCtD
Afatinib—Fatigue—Betamethasone—rheumatoid arthritis	7.49e-05	0.00108	CcSEcCtD
Afatinib—Fatigue—Dexamethasone—rheumatoid arthritis	7.49e-05	0.00108	CcSEcCtD
Afatinib—Nervous system disorder—Prednisone—rheumatoid arthritis	7.41e-05	0.00107	CcSEcCtD
Afatinib—Skin disorder—Prednisone—rheumatoid arthritis	7.34e-05	0.00106	CcSEcCtD
Afatinib—Asthenia—Hydrocortisone—rheumatoid arthritis	7.29e-05	0.00105	CcSEcCtD
Afatinib—Vomiting—Cyclosporine—rheumatoid arthritis	7.27e-05	0.00105	CcSEcCtD
Afatinib—Rash—Cyclosporine—rheumatoid arthritis	7.21e-05	0.00104	CcSEcCtD
Afatinib—Dermatitis—Cyclosporine—rheumatoid arthritis	7.2e-05	0.00104	CcSEcCtD
Afatinib—Pruritus—Hydrocortisone—rheumatoid arthritis	7.19e-05	0.00104	CcSEcCtD
Afatinib—Headache—Cyclosporine—rheumatoid arthritis	7.16e-05	0.00103	CcSEcCtD
Afatinib—Diarrhoea—Hydrocortisone—rheumatoid arthritis	6.95e-05	0.001	CcSEcCtD
Afatinib—Dizziness—Prednisolone—rheumatoid arthritis	6.88e-05	0.000993	CcSEcCtD
Afatinib—Asthenia—Triamcinolone—rheumatoid arthritis	6.87e-05	0.000991	CcSEcCtD
Afatinib—Body temperature increased—Dexamethasone—rheumatoid arthritis	6.86e-05	0.000991	CcSEcCtD
Afatinib—Body temperature increased—Betamethasone—rheumatoid arthritis	6.86e-05	0.000991	CcSEcCtD
Afatinib—Asthenia—Methylprednisolone—rheumatoid arthritis	6.85e-05	0.000989	CcSEcCtD
Afatinib—Insomnia—Prednisone—rheumatoid arthritis	6.84e-05	0.000987	CcSEcCtD
Afatinib—Nausea—Cyclosporine—rheumatoid arthritis	6.79e-05	0.00098	CcSEcCtD
Afatinib—Pruritus—Triamcinolone—rheumatoid arthritis	6.77e-05	0.000977	CcSEcCtD
Afatinib—Cough—Methotrexate—rheumatoid arthritis	6.76e-05	0.000975	CcSEcCtD
Afatinib—Pruritus—Methylprednisolone—rheumatoid arthritis	6.75e-05	0.000975	CcSEcCtD
Afatinib—Dizziness—Hydrocortisone—rheumatoid arthritis	6.72e-05	0.00097	CcSEcCtD
Afatinib—Dyspepsia—Prednisone—rheumatoid arthritis	6.66e-05	0.000961	CcSEcCtD
Afatinib—Decreased appetite—Prednisone—rheumatoid arthritis	6.57e-05	0.000949	CcSEcCtD
Afatinib—Rash—Prednisolone—rheumatoid arthritis	6.56e-05	0.000947	CcSEcCtD
Afatinib—Dermatitis—Prednisolone—rheumatoid arthritis	6.55e-05	0.000946	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—rheumatoid arthritis	6.55e-05	0.000945	CcSEcCtD
Afatinib—Diarrhoea—Methylprednisolone—rheumatoid arthritis	6.53e-05	0.000943	CcSEcCtD
Afatinib—Fatigue—Prednisone—rheumatoid arthritis	6.52e-05	0.000941	CcSEcCtD
Afatinib—Headache—Prednisolone—rheumatoid arthritis	6.52e-05	0.000941	CcSEcCtD
Afatinib—Constipation—Prednisone—rheumatoid arthritis	6.47e-05	0.000933	CcSEcCtD
Afatinib—Vomiting—Hydrocortisone—rheumatoid arthritis	6.46e-05	0.000933	CcSEcCtD
Afatinib—Rash—Hydrocortisone—rheumatoid arthritis	6.41e-05	0.000925	CcSEcCtD
Afatinib—Dermatitis—Hydrocortisone—rheumatoid arthritis	6.4e-05	0.000924	CcSEcCtD
Afatinib—Headache—Hydrocortisone—rheumatoid arthritis	6.37e-05	0.000919	CcSEcCtD
Afatinib—Dizziness—Triamcinolone—rheumatoid arthritis	6.33e-05	0.000913	CcSEcCtD
Afatinib—Dizziness—Methylprednisolone—rheumatoid arthritis	6.31e-05	0.000911	CcSEcCtD
Afatinib—Infection—Methotrexate—rheumatoid arthritis	6.28e-05	0.000906	CcSEcCtD
Afatinib—Asthenia—Betamethasone—rheumatoid arthritis	6.23e-05	0.000899	CcSEcCtD
Afatinib—Asthenia—Dexamethasone—rheumatoid arthritis	6.23e-05	0.000899	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—rheumatoid arthritis	6.2e-05	0.000894	CcSEcCtD
Afatinib—Nausea—Prednisolone—rheumatoid arthritis	6.18e-05	0.000892	CcSEcCtD
Afatinib—Pruritus—Dexamethasone—rheumatoid arthritis	6.14e-05	0.000887	CcSEcCtD
Afatinib—Pruritus—Betamethasone—rheumatoid arthritis	6.14e-05	0.000887	CcSEcCtD
Afatinib—Skin disorder—Methotrexate—rheumatoid arthritis	6.14e-05	0.000886	CcSEcCtD
Afatinib—Vomiting—Triamcinolone—rheumatoid arthritis	6.08e-05	0.000878	CcSEcCtD
Afatinib—Vomiting—Methylprednisolone—rheumatoid arthritis	6.07e-05	0.000876	CcSEcCtD
Afatinib—Nausea—Hydrocortisone—rheumatoid arthritis	6.04e-05	0.000871	CcSEcCtD
Afatinib—Rash—Triamcinolone—rheumatoid arthritis	6.03e-05	0.000871	CcSEcCtD
Afatinib—Dermatitis—Triamcinolone—rheumatoid arthritis	6.03e-05	0.00087	CcSEcCtD
Afatinib—Rash—Methylprednisolone—rheumatoid arthritis	6.02e-05	0.000869	CcSEcCtD
Afatinib—Dermatitis—Methylprednisolone—rheumatoid arthritis	6.01e-05	0.000868	CcSEcCtD
Afatinib—Headache—Triamcinolone—rheumatoid arthritis	5.99e-05	0.000865	CcSEcCtD
Afatinib—Headache—Methylprednisolone—rheumatoid arthritis	5.98e-05	0.000863	CcSEcCtD
Afatinib—Body temperature increased—Prednisone—rheumatoid arthritis	5.98e-05	0.000863	CcSEcCtD
Afatinib—Diarrhoea—Dexamethasone—rheumatoid arthritis	5.94e-05	0.000857	CcSEcCtD
Afatinib—Diarrhoea—Betamethasone—rheumatoid arthritis	5.94e-05	0.000857	CcSEcCtD
Afatinib—Dizziness—Dexamethasone—rheumatoid arthritis	5.74e-05	0.000829	CcSEcCtD
Afatinib—Dizziness—Betamethasone—rheumatoid arthritis	5.74e-05	0.000829	CcSEcCtD
Afatinib—Insomnia—Methotrexate—rheumatoid arthritis	5.72e-05	0.000825	CcSEcCtD
Afatinib—Nausea—Triamcinolone—rheumatoid arthritis	5.68e-05	0.00082	CcSEcCtD
Afatinib—Nausea—Methylprednisolone—rheumatoid arthritis	5.67e-05	0.000819	CcSEcCtD
Afatinib—Dyspnoea—Methotrexate—rheumatoid arthritis	5.63e-05	0.000813	CcSEcCtD
Afatinib—Dyspepsia—Methotrexate—rheumatoid arthritis	5.56e-05	0.000803	CcSEcCtD
Afatinib—Vomiting—Betamethasone—rheumatoid arthritis	5.52e-05	0.000797	CcSEcCtD
Afatinib—Vomiting—Dexamethasone—rheumatoid arthritis	5.52e-05	0.000797	CcSEcCtD
Afatinib—Decreased appetite—Methotrexate—rheumatoid arthritis	5.49e-05	0.000793	CcSEcCtD
Afatinib—Rash—Betamethasone—rheumatoid arthritis	5.47e-05	0.00079	CcSEcCtD
Afatinib—Rash—Dexamethasone—rheumatoid arthritis	5.47e-05	0.00079	CcSEcCtD
Afatinib—Dermatitis—Betamethasone—rheumatoid arthritis	5.47e-05	0.000789	CcSEcCtD
Afatinib—Dermatitis—Dexamethasone—rheumatoid arthritis	5.47e-05	0.000789	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methotrexate—rheumatoid arthritis	5.46e-05	0.000787	CcSEcCtD
Afatinib—Fatigue—Methotrexate—rheumatoid arthritis	5.45e-05	0.000786	CcSEcCtD
Afatinib—Headache—Dexamethasone—rheumatoid arthritis	5.44e-05	0.000785	CcSEcCtD
Afatinib—Headache—Betamethasone—rheumatoid arthritis	5.44e-05	0.000785	CcSEcCtD
Afatinib—Asthenia—Prednisone—rheumatoid arthritis	5.42e-05	0.000783	CcSEcCtD
Afatinib—Pruritus—Prednisone—rheumatoid arthritis	5.35e-05	0.000772	CcSEcCtD
Afatinib—Diarrhoea—Prednisone—rheumatoid arthritis	5.17e-05	0.000747	CcSEcCtD
Afatinib—Nausea—Dexamethasone—rheumatoid arthritis	5.16e-05	0.000744	CcSEcCtD
Afatinib—Nausea—Betamethasone—rheumatoid arthritis	5.16e-05	0.000744	CcSEcCtD
Afatinib—Dizziness—Prednisone—rheumatoid arthritis	5e-05	0.000722	CcSEcCtD
Afatinib—Body temperature increased—Methotrexate—rheumatoid arthritis	5e-05	0.000721	CcSEcCtD
Afatinib—Vomiting—Prednisone—rheumatoid arthritis	4.81e-05	0.000694	CcSEcCtD
Afatinib—Rash—Prednisone—rheumatoid arthritis	4.77e-05	0.000688	CcSEcCtD
Afatinib—Dermatitis—Prednisone—rheumatoid arthritis	4.76e-05	0.000687	CcSEcCtD
Afatinib—Headache—Prednisone—rheumatoid arthritis	4.74e-05	0.000684	CcSEcCtD
Afatinib—Asthenia—Methotrexate—rheumatoid arthritis	4.53e-05	0.000654	CcSEcCtD
Afatinib—Nausea—Prednisone—rheumatoid arthritis	4.49e-05	0.000648	CcSEcCtD
Afatinib—Pruritus—Methotrexate—rheumatoid arthritis	4.47e-05	0.000645	CcSEcCtD
Afatinib—Diarrhoea—Methotrexate—rheumatoid arthritis	4.32e-05	0.000624	CcSEcCtD
Afatinib—Dizziness—Methotrexate—rheumatoid arthritis	4.18e-05	0.000603	CcSEcCtD
Afatinib—Vomiting—Methotrexate—rheumatoid arthritis	4.02e-05	0.00058	CcSEcCtD
Afatinib—Rash—Methotrexate—rheumatoid arthritis	3.98e-05	0.000575	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—rheumatoid arthritis	3.98e-05	0.000575	CcSEcCtD
Afatinib—Headache—Methotrexate—rheumatoid arthritis	3.96e-05	0.000571	CcSEcCtD
Afatinib—Nausea—Methotrexate—rheumatoid arthritis	3.75e-05	0.000542	CcSEcCtD
Afatinib—LCK—Signaling by NGF—IL6—rheumatoid arthritis	4.11e-06	3.31e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CD28—rheumatoid arthritis	4.11e-06	3.31e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—C3—rheumatoid arthritis	4.08e-06	3.28e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-A—rheumatoid arthritis	4.06e-06	3.27e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IFNG—rheumatoid arthritis	4.06e-06	3.27e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCR5—rheumatoid arthritis	4.03e-06	3.25e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD80—rheumatoid arthritis	4.01e-06	3.23e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—UBE2D1—rheumatoid arthritis	4.01e-06	3.23e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TNF—rheumatoid arthritis	3.99e-06	3.22e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—VEGFA—rheumatoid arthritis	3.98e-06	3.21e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2RA—rheumatoid arthritis	3.97e-06	3.2e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2RA—rheumatoid arthritis	3.96e-06	3.19e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—rheumatoid arthritis	3.94e-06	3.18e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—C3—rheumatoid arthritis	3.94e-06	3.17e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL12—rheumatoid arthritis	3.93e-06	3.17e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BDKRB2—rheumatoid arthritis	3.93e-06	3.17e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—C3—rheumatoid arthritis	3.93e-06	3.16e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—B3GNT2—rheumatoid arthritis	3.92e-06	3.16e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ACP5—rheumatoid arthritis	3.92e-06	3.16e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD4—rheumatoid arthritis	3.92e-06	3.16e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-A—rheumatoid arthritis	3.92e-06	3.16e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6ST—rheumatoid arthritis	3.9e-06	3.14e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ADRBK1—rheumatoid arthritis	3.89e-06	3.13e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CRP—rheumatoid arthritis	3.88e-06	3.12e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—NFKB1—rheumatoid arthritis	3.87e-06	3.12e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TYK2—rheumatoid arthritis	3.87e-06	3.12e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—UBE2D1—rheumatoid arthritis	3.87e-06	3.11e-05	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—IL6—rheumatoid arthritis	3.86e-06	3.11e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CCR5—rheumatoid arthritis	3.85e-06	3.1e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TYK2—rheumatoid arthritis	3.82e-06	3.07e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—MAPK8—rheumatoid arthritis	3.81e-06	3.07e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NOS3—rheumatoid arthritis	3.8e-06	3.06e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL12—rheumatoid arthritis	3.79e-06	3.05e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BDKRB2—rheumatoid arthritis	3.79e-06	3.05e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—VEGFA—rheumatoid arthritis	3.76e-06	3.03e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MTHFR—rheumatoid arthritis	3.76e-06	3.03e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HLA-A—rheumatoid arthritis	3.75e-06	3.02e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ADRBK1—rheumatoid arthritis	3.75e-06	3.02e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NOS3—rheumatoid arthritis	3.74e-06	3.02e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CRP—rheumatoid arthritis	3.74e-06	3.01e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—NFKB1—rheumatoid arthritis	3.73e-06	3.01e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6R—rheumatoid arthritis	3.72e-06	3e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—NFKB1—rheumatoid arthritis	3.72e-06	3e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—TLR4—rheumatoid arthritis	3.72e-06	2.99e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-DRB1—rheumatoid arthritis	3.71e-06	2.99e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CCR5—rheumatoid arthritis	3.71e-06	2.99e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—rheumatoid arthritis	3.68e-06	2.97e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—MAPK8—rheumatoid arthritis	3.67e-06	2.96e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RASGRP1—rheumatoid arthritis	3.67e-06	2.96e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—LEP—rheumatoid arthritis	3.67e-06	2.96e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SYK—rheumatoid arthritis	3.66e-06	2.95e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TGFB1—rheumatoid arthritis	3.65e-06	2.94e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—IL6—rheumatoid arthritis	3.64e-06	2.93e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MTHFR—rheumatoid arthritis	3.63e-06	2.92e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL1B—rheumatoid arthritis	3.62e-06	2.91e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HLA-A—rheumatoid arthritis	3.62e-06	2.91e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL2—rheumatoid arthritis	3.6e-06	2.9e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PRKCQ—rheumatoid arthritis	3.59e-06	2.89e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—TGFB1—rheumatoid arthritis	3.59e-06	2.89e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—NFKB1—rheumatoid arthritis	3.59e-06	2.89e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—TLR4—rheumatoid arthritis	3.58e-06	2.89e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-DRB1—rheumatoid arthritis	3.58e-06	2.88e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—POMC—rheumatoid arthritis	3.57e-06	2.87e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—ICAM1—rheumatoid arthritis	3.56e-06	2.87e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6ST—rheumatoid arthritis	3.56e-06	2.87e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RASGRP1—rheumatoid arthritis	3.54e-06	2.85e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—TGFB1—rheumatoid arthritis	3.54e-06	2.85e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—BGN—rheumatoid arthritis	3.53e-06	2.84e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT1—rheumatoid arthritis	3.53e-06	2.84e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CAT—rheumatoid arthritis	3.53e-06	2.84e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SYK—rheumatoid arthritis	3.52e-06	2.84e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CCL2—rheumatoid arthritis	3.49e-06	2.81e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6R—rheumatoid arthritis	3.48e-06	2.8e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL10—rheumatoid arthritis	3.48e-06	2.8e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PRKCQ—rheumatoid arthritis	3.46e-06	2.79e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FN1—rheumatoid arthritis	3.46e-06	2.79e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TGFB1—rheumatoid arthritis	3.45e-06	2.78e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—rheumatoid arthritis	3.45e-06	2.78e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6ST—rheumatoid arthritis	3.45e-06	2.78e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6ST—rheumatoid arthritis	3.43e-06	2.77e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ICAM1—rheumatoid arthritis	3.43e-06	2.77e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD80—rheumatoid arthritis	3.43e-06	2.76e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TNF—rheumatoid arthritis	3.41e-06	2.75e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT1—rheumatoid arthritis	3.4e-06	2.74e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—TYK2—rheumatoid arthritis	3.39e-06	2.73e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—NFKB1—rheumatoid arthritis	3.37e-06	2.72e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CXCL8—rheumatoid arthritis	3.37e-06	2.72e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL10—rheumatoid arthritis	3.35e-06	2.7e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CXCL8—rheumatoid arthritis	3.32e-06	2.68e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—MAPK8—rheumatoid arthritis	3.32e-06	2.67e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CD80—rheumatoid arthritis	3.32e-06	2.67e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CD80—rheumatoid arthritis	3.31e-06	2.66e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6ST—rheumatoid arthritis	3.29e-06	2.65e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NOS2—rheumatoid arthritis	3.26e-06	2.63e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALOX5—rheumatoid arthritis	3.25e-06	2.62e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—rheumatoid arthritis	3.25e-06	2.62e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL2—rheumatoid arthritis	3.22e-06	2.6e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—IL6—rheumatoid arthritis	3.22e-06	2.6e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6R—rheumatoid arthritis	3.18e-06	2.56e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL2—rheumatoid arthritis	3.17e-06	2.56e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IFNG—rheumatoid arthritis	3.17e-06	2.56e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP3—rheumatoid arthritis	3.17e-06	2.55e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6ST—rheumatoid arthritis	3.17e-06	2.55e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—TYK2—rheumatoid arthritis	3.17e-06	2.55e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CD80—rheumatoid arthritis	3.17e-06	2.55e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—POMC—rheumatoid arthritis	3.15e-06	2.54e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NOS2—rheumatoid arthritis	3.15e-06	2.53e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCL2—rheumatoid arthritis	3.08e-06	2.48e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6R—rheumatoid arthritis	3.07e-06	2.48e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD4—rheumatoid arthritis	3.07e-06	2.47e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6R—rheumatoid arthritis	3.06e-06	2.47e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP3—rheumatoid arthritis	3.06e-06	2.46e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTK2—rheumatoid arthritis	3.05e-06	2.46e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CD80—rheumatoid arthritis	3.05e-06	2.46e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MMP9—rheumatoid arthritis	3.05e-06	2.46e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NFKB1—rheumatoid arthritis	3.02e-06	2.43e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MMP9—rheumatoid arthritis	3e-06	2.42e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL5—rheumatoid arthritis	2.99e-06	2.41e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NFKB1—rheumatoid arthritis	2.97e-06	2.39e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MAPK8—rheumatoid arthritis	2.97e-06	2.39e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CSF2—rheumatoid arthritis	2.95e-06	2.38e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—MTHFR—rheumatoid arthritis	2.94e-06	2.37e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTK2—rheumatoid arthritis	2.94e-06	2.37e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6R—rheumatoid arthritis	2.94e-06	2.37e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL6—rheumatoid arthritis	2.93e-06	2.36e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MAPK8—rheumatoid arthritis	2.92e-06	2.35e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—TYK2—rheumatoid arthritis	2.9e-06	2.33e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL6—rheumatoid arthritis	2.89e-06	2.32e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL5—rheumatoid arthritis	2.88e-06	2.32e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—IL6—rheumatoid arthritis	2.85e-06	2.29e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—rheumatoid arthritis	2.84e-06	2.29e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CSF2—rheumatoid arthritis	2.84e-06	2.29e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL1B—rheumatoid arthritis	2.83e-06	2.28e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6R—rheumatoid arthritis	2.83e-06	2.28e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL2—rheumatoid arthritis	2.82e-06	2.27e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TYK2—rheumatoid arthritis	2.8e-06	2.26e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—TYK2—rheumatoid arthritis	2.79e-06	2.25e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL6—rheumatoid arthritis	2.78e-06	2.24e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SPP1—rheumatoid arthritis	2.77e-06	2.23e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CXCL8—rheumatoid arthritis	2.76e-06	2.22e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—IL6—rheumatoid arthritis	2.75e-06	2.22e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NOS3—rheumatoid arthritis	2.75e-06	2.21e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—rheumatoid arthritis	2.74e-06	2.21e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IFNG—rheumatoid arthritis	2.71e-06	2.18e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—IL6—rheumatoid arthritis	2.71e-06	2.18e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—rheumatoid arthritis	2.7e-06	2.17e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCR5—rheumatoid arthritis	2.7e-06	2.17e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TYK2—rheumatoid arthritis	2.67e-06	2.15e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SPP1—rheumatoid arthritis	2.67e-06	2.15e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—IL6—rheumatoid arthritis	2.66e-06	2.15e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2RA—rheumatoid arthritis	2.66e-06	2.14e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ENO1—rheumatoid arthritis	2.65e-06	2.13e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—NFKB1—rheumatoid arthritis	2.64e-06	2.13e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL2—rheumatoid arthritis	2.64e-06	2.12e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—C3—rheumatoid arthritis	2.64e-06	2.12e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NOS3—rheumatoid arthritis	2.62e-06	2.11e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD4—rheumatoid arthritis	2.62e-06	2.11e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IFNG—rheumatoid arthritis	2.61e-06	2.11e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCR5—rheumatoid arthritis	2.6e-06	2.09e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK8—rheumatoid arthritis	2.6e-06	2.09e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TYK2—rheumatoid arthritis	2.58e-06	2.08e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2RA—rheumatoid arthritis	2.56e-06	2.06e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—C3—rheumatoid arthritis	2.54e-06	2.05e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NOS3—rheumatoid arthritis	2.53e-06	2.04e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CD4—rheumatoid arthritis	2.52e-06	2.03e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TGFB1—rheumatoid arthritis	2.51e-06	2.03e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ALB—rheumatoid arthritis	2.48e-06	1.99e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TGFB1—rheumatoid arthritis	2.48e-06	1.99e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—LEP—rheumatoid arthritis	2.45e-06	1.98e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL8—rheumatoid arthritis	2.44e-06	1.96e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—rheumatoid arthritis	2.43e-06	1.96e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1B—rheumatoid arthritis	2.42e-06	1.95e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CD4—rheumatoid arthritis	2.42e-06	1.95e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2—rheumatoid arthritis	2.41e-06	1.94e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—rheumatoid arthritis	2.4e-06	1.93e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—LEP—rheumatoid arthritis	2.36e-06	1.9e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—POMC—rheumatoid arthritis	2.35e-06	1.9e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—rheumatoid arthritis	2.34e-06	1.89e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1B—rheumatoid arthritis	2.33e-06	1.88e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CD4—rheumatoid arthritis	2.33e-06	1.88e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—rheumatoid arthritis	2.33e-06	1.88e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—rheumatoid arthritis	2.32e-06	1.87e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FN1—rheumatoid arthritis	2.31e-06	1.86e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—rheumatoid arthritis	2.31e-06	1.86e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6ST—rheumatoid arthritis	2.3e-06	1.86e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—NFKB1—rheumatoid arthritis	2.26e-06	1.82e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FN1—rheumatoid arthritis	2.23e-06	1.8e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6ST—rheumatoid arthritis	2.22e-06	1.79e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK8—rheumatoid arthritis	2.22e-06	1.79e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CD80—rheumatoid arthritis	2.22e-06	1.79e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—rheumatoid arthritis	2.21e-06	1.78e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NFKB1—rheumatoid arthritis	2.18e-06	1.76e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NFKB1—rheumatoid arthritis	2.17e-06	1.75e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ALB—rheumatoid arthritis	2.15e-06	1.73e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK8—rheumatoid arthritis	2.14e-06	1.73e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK8—rheumatoid arthritis	2.14e-06	1.72e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CD80—rheumatoid arthritis	2.14e-06	1.72e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—rheumatoid arthritis	2.12e-06	1.71e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—POMC—rheumatoid arthritis	2.11e-06	1.7e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—rheumatoid arthritis	2.07e-06	1.67e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL2—rheumatoid arthritis	2.06e-06	1.66e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6R—rheumatoid arthritis	2.06e-06	1.66e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—NOS3—rheumatoid arthritis	2.05e-06	1.65e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—rheumatoid arthritis	2.04e-06	1.64e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—POMC—rheumatoid arthritis	2.03e-06	1.64e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL2—rheumatoid arthritis	1.99e-06	1.6e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6R—rheumatoid arthritis	1.98e-06	1.6e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—rheumatoid arthritis	1.98e-06	1.6e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CAT—rheumatoid arthritis	1.91e-06	1.54e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—rheumatoid arthritis	1.89e-06	1.53e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—rheumatoid arthritis	1.88e-06	1.51e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TYK2—rheumatoid arthritis	1.87e-06	1.51e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—rheumatoid arthritis	1.87e-06	1.5e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOS3—rheumatoid arthritis	1.84e-06	1.48e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TGFB1—rheumatoid arthritis	1.82e-06	1.46e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TYK2—rheumatoid arthritis	1.8e-06	1.45e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOS3—rheumatoid arthritis	1.77e-06	1.43e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFB1—rheumatoid arthritis	1.74e-06	1.4e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TGFB1—rheumatoid arthritis	1.67e-06	1.35e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—rheumatoid arthritis	1.66e-06	1.34e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL8—rheumatoid arthritis	1.63e-06	1.31e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTHFR—rheumatoid arthritis	1.59e-06	1.28e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL8—rheumatoid arthritis	1.57e-06	1.27e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—rheumatoid arthritis	1.56e-06	1.26e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—rheumatoid arthritis	1.55e-06	1.25e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—rheumatoid arthritis	1.5e-06	1.21e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—rheumatoid arthritis	1.5e-06	1.21e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—rheumatoid arthritis	1.47e-06	1.19e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NFKB1—rheumatoid arthritis	1.46e-06	1.18e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK8—rheumatoid arthritis	1.43e-06	1.16e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—rheumatoid arthritis	1.42e-06	1.14e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—rheumatoid arthritis	1.42e-06	1.14e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NFKB1—rheumatoid arthritis	1.41e-06	1.13e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK8—rheumatoid arthritis	1.38e-06	1.11e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—rheumatoid arthritis	1.37e-06	1.1e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—rheumatoid arthritis	1.37e-06	1.1e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—rheumatoid arthritis	1.32e-06	1.07e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—rheumatoid arthritis	1.31e-06	1.05e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—rheumatoid arthritis	1.28e-06	1.03e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—POMC—rheumatoid arthritis	1.27e-06	1.02e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—rheumatoid arthritis	1.26e-06	1.02e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TGFB1—rheumatoid arthritis	1.22e-06	9.79e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFB1—rheumatoid arthritis	1.17e-06	9.44e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALB—rheumatoid arthritis	1.16e-06	9.34e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NOS3—rheumatoid arthritis	1.11e-06	8.94e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—rheumatoid arthritis	1.01e-06	8.17e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—rheumatoid arthritis	1e-06	8.06e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—rheumatoid arthritis	9.64e-07	7.77e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—rheumatoid arthritis	9.16e-07	7.38e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—rheumatoid arthritis	8.83e-07	7.11e-06	CbGpPWpGaD
